In this SOHO Insider interview from the American Society of Hematology Annual Meeting & Exposition, Lore Gruenbaum, PhD, chief scientific officer at Blood Cancer United, discusses how menin inhibitors, initially approved in the relapsed or refractory setting, are now moving into frontline combinations with intensive chemotherapy.
Early data show higher response rates and encouraging durability, particularly in NPM1-mutated or KMT2A-rearranged AML. She also notes emerging differences in side effect profiles among agents and the potential for further combinations with other targeted therapies.
